PRIMARY STUDY
Clinical Utility of a Biomarker to Detect Contrast-Induced Acute Kidney Injury during Percutaneous Cardiovascular Proceduresv
Key Findings: Using the biomarker liver-type fatty acid-binding protein (L-FABP) during cardiovascular procedures could provide more accurate and earlier identification of early kidney compromise due to iodinated contract exposure.
Type of Study: Clinical Trial
Study Sample Size: 154
Study Result: Positive
Research Location(s): Japan, United States
Year of Pub: 2022
Cannabinoids Studied: Fatty Acid-Binding Protein (FABP)
Phytocannabinoid Source: Not Applicable
Route of Administration: Endogenous
Citation: Peabody J, et al. Clinical Utility of a Biomarker to Detect Contrast-Induced Acute Kidney Injury during Percutaneous Cardiovascular Procedures. Cardiorenal Med. 2022; 12:11-19. doi: 10.1159/000520820
Authors: Peabody J, Paculdo D, Valdenor C, McCullough PA, Noiri E, Sugaya T, Dahlen JR
